AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Probable ubiquitin carboxyl-terminal hydrolase MINDY-4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q4G0A6

UPID:

MINY4_HUMAN

Alternative names:

Probable deubiquitinating enzyme MINDY-4

Alternative UPACC:

Q4G0A6; Q71AZ7; Q9H6D2

Background:

Probable ubiquitin carboxyl-terminal hydrolase MINDY-4, also known as a probable deubiquitinating enzyme MINDY-4, plays a crucial role in cellular processes through its probable hydrolase activity, which can remove 'Lys-48'-linked conjugated ubiquitin from proteins. This specific activity is vital for the regulation of ubiquitin-dependent signaling pathways, influencing protein degradation, DNA repair, cell cycle, and immune response.

Therapeutic significance:

Understanding the role of Probable ubiquitin carboxyl-terminal hydrolase MINDY-4 could open doors to potential therapeutic strategies. Its involvement in the precise regulation of protein degradation and signaling pathways presents an opportunity for the development of novel treatments targeting diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.